International Journal of Clinical Pharmacy

, Volume 33, Issue 2, pp 246–251 | Cite as

The outpatient utilization of non-steroidal anti-inflammatory drugs in South Bačka District, Serbia

  • Jelena ĆalasanEmail author
  • Vesna Mijatović
  • Olga Horvat
  • Jan Varga
  • Ana Sabo
  • Nebojša Stilinović
Research Article


Objective To evaluate the utilization of non-steroidal anti-inflammatory drugs (NSAIDs) in South Bačka District (SBD), Serbia. Setting State-owned and private pharmacies in SBD, a northern district of Serbia, with 605,720 inhabitants (according to the 2008 census). Method Data on the number of packages, size of packages, and retail price of NSAIDs (Anatomical Therapeutic Chemical (ATC) group M01A) from 1 January to 31 March 2008 were obtained from all state-owned and private pharmacies in SBD. This included NSAIDs bought without prescription and those issued by prescription (on the Health Insurance Companies List for Reimbursement). The number of defined daily doses/1000 inhabitants/day (DDD/1000 inh/day) was calculated. Within the DU90% (drug utilization 90%) segment, the proportion of high-, medium- and low-risk NSAIDs with respect to the risk of gastrointestinal (GI) bleeding was determined. Price/DDD was also calculated. Main outcome measure Consumption of drugs expressed as DDD/1000 inh/day. Results The total consumption of NSAIDs over a 3-month period was 48.31 DDD/1000 inh/day. Only four drugs were within DU90%: diclofenac, ibuprofen, nimesulide and meloxicam (62.14, 19.87, 5.77, and 5.73% of total NSAID consumption, respectively). All dispensed NSAIDs within the DU90% segment except nimesulide (which was exclusively purchased without prescription) were nearly equally purchased without prescription and issued by prescription. The average price per DDD within the DU90% segment was 0.17 Euro/DDD, whereas it was 0.30 Euro/DDD for NSAIDs beyond the DU90% segment. The pattern of use of NSAIDs according to their GI risk showed that medium-risk diclofenac accounted for 66.45%, whereas low-risk ibuprofen was estimated to be 21.25% within the DU90% segment. Conclusion Factors other than evidence-based medicine (such as poor health education in the past that led to long-lasting consequences on the cultural behaviour of the general population as well as on the prescribing habits of physicians) have a dominating impact on the use of NSAIDs in SBD. Targeted education from independent sources in the prescribing, dispensing and use of drugs is required to improve the quality of prescription and use of NSAIDs in Serbia.


ATC/DDD methodology Drug utilization NSAIDs Pharmacoepidemiology Serbia 



This research is part of the project No. 41012 which is financially supported by the Ministry of Science of the Republic of Serbia.


The present study received no external funding.

Conflicts of interest

All authors of this manuscript declare they had no conflicts of interest in connection with this study.


  1. 1.
    Erdeljic V, Francetic I, Sarinic V, Bilusic M, Ausperger K, Huic M, et al. Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study. Pharm World Sci. 2006;28:318–25.PubMedCrossRefGoogle Scholar
  2. 2.
    Lai LH, Chan FK. Non-steroidal anti-inflammatory drug-induced gastroduodenal injury. Curr Opin Gastroenterol. 2009;25(6):544–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Sostres C, Gargallo C, Arroyo M, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:121–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Walker SL, Kennedy F, Niamh N, McCormick PA. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf. 2008;17:1108–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf. 2010;19:708–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Van Staa TP, Rietbrack S, Setakis E, Leufkens. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med. 2008;264(5):481–92.PubMedCrossRefGoogle Scholar
  7. 7.
    McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. Systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA. 2006;296(13):1633–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Committee on Safety of Medicines/Medicines Control Agency. Relative safety of oral non-aspirin NSAIDs. Curr Probl. 1994;20:9–11.Google Scholar
  9. 9.
    Committee on Safety of Medicines/Medicines Control Agency. Non-Steroidal anti-inflammatory drugs (NSAIDs) and gastrointestinal (GI) safety. Curr Probl. 2002;28:5.Google Scholar
  10. 10.
    Bergman U, Andersen M, Vaccheri A, et al. Deviations from evidence-based prescribing of non-steroidal anti-inflammatory drugs in three European regions. Eur J Clin Pharmacol. 2000;56(3):269–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Dubois R, Melmed G, Henning J, et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19(2):197–208.PubMedCrossRefGoogle Scholar
  12. 12.
    Rahme E, Joseph L, Kong SX, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum. 2000;43:917–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Mijatović V, Ćalasan J, Horvat O, Sabo A, Tomić Z, Radulović V. Consumption of non–steroidal anti-inflammatory drugs in Serbia compared with Croatia and Denmark during 2005–2008 period. Eur J Clin Pharmacol. 2011;67(2):203–7.PubMedCrossRefGoogle Scholar
  14. 14.
    World Health Organization Collaborating Centre for Drug Statistics Metodology. About the ATC/DDD system. Accessed 16 March 2009.
  15. 15.
    Bergman U, Popa C, Tomson Y, et al. Drug utilization–a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol. 1998;54:113–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Vlahovic-Palcevski V, Wettermark B, Bergman U, et al. Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm). Eur J Clin Pharmacol. 2002;58:209–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Inotai A, Hankó B, Mészáros A. Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiol Drug Saf. 2010;19(2):183–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Danish Medicines Agency. Medicinal Products Statistics in Denmark 2004–2008. Sales within the different ATC groups, primary healthcare sector. Accessed 21 March 2009.
  19. 19.
    Sallmann A. The history of diclofenac. Am J Med. 1986;80(4B):29–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26(7):1715–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med. 2001;110(1A):4S–7S.PubMedCrossRefGoogle Scholar
  22. 22.
    National Prescribing Centre. England. Encouraging prescribing trends for NSAIDs. Accessed 21 March 2010.
  23. 23.
    National Prescribing Centre. England. Update on the prescribing of NSAIDs. Accessed 18 March 2010.
  24. 24.
    Hudec R, Kriska M, Bozekova L, et al. Comparison of NSAID consumption in Slovakia, Finland and Norway. Bratis Lek Listy. 2008;109(8):370–3.Google Scholar
  25. 25.
    Republic of Montenegro. Health Insurance Fund. Outpatient consumption of medicines. Accessed 18 March 2010.
  26. 26.
    Republic of Croatia. Agency for medicinal product and medical devices. Annual report on drug consumption for 2008. Accessed 1 Aug 2010.
  27. 27.
    European Medicines Agency. The United Kingdom. European Medicines Agency recommends restricted use of nimesulide-containing medicinal products. Accessed 21 March 2010.
  28. 28.
    Ibanez-Cuevas V, Lopez-Briz E, Guardiola-Chorro MT. Pharmacist intervention reduces gastropathy risk in patients using NSAIDs. Pharm World Sci. 2008;30:947–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal antiinflammatory drugs. J Gen Intern Med. 1996;11:461–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Jelena Ćalasan
    • 1
    Email author
  • Vesna Mijatović
    • 1
  • Olga Horvat
    • 1
  • Jan Varga
    • 2
  • Ana Sabo
    • 1
  • Nebojša Stilinović
    • 1
  1. 1.Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of MedicineUniversity of Novi SadNovi SadSerbia
  2. 2.Institute for Health Protection of Children and Youth of VojvodinaNovi SadSerbia

Personalised recommendations